Counterfeit Ozempic in 2026: how drug makers can protect the supply chain

Counterfeit Ozempic has moved from a fringe risk to a front-page patient-safety problem. In 2026, fakes copied packaging, labels and even needles well enough to trigger an FDA public alert and criminal charges — and INTERPOL's Operation Pangea XVIII drove millions in global seizures of falsified medicines.

Why serialization alone isn't enough

Serialization and track-and-trace prove a pack existed in your system. They don't give a pharmacist or patient an easy, hardware-free way to confirm the unit in their hand is genuine — and they say nothing about whether a temperature-sensitive biologic stayed in-spec.

A defense-in-depth remedy

TAGUARD adds two layers on top of your existing compliance:

• ChaosMark authentication gives each carton or vial a copy-resistant identity, verified with a smartphone tap.
• TAG K5PT BLE beacons log temperature and alert on 2–8 °C excursions across distribution, with the TAG GT01 gateway capturing data in real time.

Together they turn "trust us" into "verify it" — for regulators, pharmacists and patients alike.

See the pharma solution →